Essential fatty acids in diabetes and systemic lupus erythematosus (SLE) patients.
Sera obtained from normal subjects and juvenile-onset diabetes (JD) and systemic lupus erythromatus (SLE) patients were examined for free fatty acid composition and 6-keto-PGF1 alpha content. In addition, prostaglandins in urine samples from normal and diabetic individuals were separated by HPLC, and 6-keto-PGF1 alpha levels were monitored by RIA. Arachidonate (20:4) content in diabetic and SLE individuals were significantly lower than that of controls. Urine from diabetic individuals showed decreased levels of 6-keto-PG F1 alpha. The study also indicated that RIA measurements on crude biological samples may yield erroneous data due to immune cross reactivity with other compounds.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000652:urine; D005228:Fatty Acids, Essential / Q000097:blood*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D011863:Radioimmunoassay
D005228:Fatty Acids, Essential; D005230:Fatty Acids, Nonesterified; D015121:6-Ketoprostaglandin F1 alpha